Stability of doxorubicin combined with Radioselectan®, a contrast agent, for chemoembolization

被引:1
作者
Chiadmi, F
Daroso, J
Schlatter, J
Cisternino, S
Ratiney, R
Fontan, JE
机构
[1] Univ Hosp Jean Verdier, Dept Pharmacol & Toxicol, F-93140 Bondy, France
[2] Univ Hosp Rene Muret, Dept Pharm, Sevran, France
关键词
chemoembolization; doxorubicin; Radioselectan((R)); stability;
D O I
10.1111/j.1365-2710.2005.00654.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To assess the stability of doxorubicin combined with Radioselectan((R)). Methods: Solutions of doxorubicin 5 mg/mL were prepared from commercially available 50 mg powder with 10 mL of Radioselectan((R)). They were stored in glass syringes at 4, 25 and 45 degrees C. The concentrations of doxorubicin were determined using a stability-indicating high-performance liquid chromatography method. The initial and final pHs of solutions were compared. The times (t(90)) needed for doxorubicin to fall to 90% of its initial concentration were calculated by a linear regression analysis. Results: The t(90) [95% confidence limits] were 79 [75-83], 56 [53-59] and 22 [21-23] hours for the solutions stored at 4, 25 and 40 degrees C respectively. The initial pH of the solutions stored at 4, 25 and 40 degrees C were 6.52, 6.50 and 6.51 respectively. The final pH of solutions stored at 25 and 40 degrees C decreased significantly by 0.3 and 0.9 respectively. No change of pH solution stored at 4 degrees C was observed. Conclusion: Doxorubicin combined with Radioselectan((R)) stored at room temperature is stable for 48 h.
引用
收藏
页码:255 / 258
页数:4
相关论文
共 9 条
[1]   Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma:: Results of a randomized, controlled trial in a single institution [J].
Bruix, J ;
Llovet, JM ;
Castells, A ;
Montañá, X ;
Brú, C ;
Ayuso, MD ;
Vilana, R ;
Rodés, J .
HEPATOLOGY, 1998, 27 (06) :1578-1583
[2]   Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography [J].
Chin, DL ;
Lum, BL ;
Sikic, BI .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 779 (02) :259-269
[3]   Increased cytotoxicity and stability of Lipiodol-pirarubicin emulsion compared to classical doxorubicin-Lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinoma [J].
Favoulet, P ;
Cercueil, JP ;
Faure, P ;
Osmak, L ;
Isambert, N ;
Beltramo, JL ;
Cognet, F ;
Krause, D ;
Bedenne, L ;
Chauffert, B .
ANTI-CANCER DRUGS, 2001, 12 (10) :801-806
[4]  
Mayer MI, 2001, ANN PHARMACOTHER, V35, P1548
[5]   A RANDOMIZED TRIAL OF HEPATIC ARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR-CARCINOMA [J].
PELLETIER, G ;
ROCHE, A ;
INK, O ;
ANCIAUX, ML ;
DERHY, S ;
ROUGIER, P ;
LENOIR, C ;
ATTALI, P ;
ETIENNE, JP .
JOURNAL OF HEPATOLOGY, 1990, 11 (02) :181-184
[6]   Chemoembolisation with lipiodol and doxorubicin: Applicability in British patients with hepatocellular carcinoma [J].
Ryder, SD ;
Rizzi, PM ;
Metivier, E ;
Karani, J ;
Williams, R .
GUT, 1996, 38 (01) :125-128
[7]   Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization [J].
Seong, J ;
Park, HC ;
Han, KH ;
Lee, DY ;
Lee, JT ;
Chon, CY ;
Moon, YM ;
Suh, CO .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (05) :1331-1335
[8]   STABILITY STUDIES ON CHEMOEMBOLIZATION MIXTURES - DIALYSIS STUDIES OF DOXORUBICIN AND LIPIODOL WITH AVITENE, GELFOAM, AND ANGIOSTAT [J].
STRUK, D ;
RANKIN, RN ;
KARLIK, SJ .
INVESTIGATIVE RADIOLOGY, 1993, 28 (11) :1024-1027
[9]  
VANBEERS B, 1989, ACTA RADIOL, V30, P415